21 results about "Antibody mimetic" patented technology

The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dosage regimens and compositions for use in such methods.

The present invention relates to chimeric receptors that can be used in whole-cell sensors for detecting analytes of interest. The inventors showed that the DNA binding domains and downstream gene expression can be activated via dimerization of an artificial dimerization composed of a single chain variable domain. They demonstrated for the first time that an artificial bacterial receptor using an antibody-like domain can be activated and produce a transcriptional output upon ligand-binding. In particular, the present invention relates to a chimeric receptor polypeptide comprising: i) a first DNA binding domain, ii) at least one binding domain selected from the group consisting of heavy chain variable domain, camelid VHHs, or antibody mimetics having specificity for an analyte, and iii) a linker between the DNA binding domain and the binding domain.

The present application provides a polypeptide with binding affinity to HPV18 E6 protein, taking the Z domain of staphylococcal protein A as a scaffold, randomly mutating the surface amino acid residues to simulate antibody binding sites, constructing a mutant library through phage display technology, screening the library through affinity with HPV18 E6 as a target antigen, and finally obtaining a polypeptide with high affinity to HPV18 E6 through a large number of screening work. Through in-depth research, the present application first discloses a polypeptide with binding affinity to the E6 protein of HPV18. In addition, the present application also provides the diagnostic or therapeutic use of the polypeptide as a drug or molecular targeting reagent.

Vascular endothelial growth factor receptors (VEGFRs) inhibitors, in particular VEGFR-1 inhibitors, for use in promoting myelination and / or neuroprotection in a subject. Such VEGR-1 inhibitors include small organic molecules, peptides, antibodies, antibody fragments, antibody mimetics, or nucleic acids. Also, compositions, pharmaceutical compositions, medicaments and kits of parts that include VEGFR-1 inhibitors and their use for promoting myelination and / or neuroprotection in a subject.

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

Provided are transition metal dichalcogenide (TMD)-based antibody mimetic comprising: a transition metal dichalcogenide nanosheet; and a tripeptide bound to the nanosheet. The antibody mimetic according to the present invention can strongly bind to PD-L1 with a dissociation constant at the nanomolar level, and can selectively bind to albumin and immunoglobulin (IgG1), which are major plasma proteins, at least 1.5 times more selectively. As a result, imaging of PD-L1-overexpressing cancer cells is possible by treating PD-L1-overexpressing cancer cells with a TMD nanosheet antibody mimic so as to detect the Raman scattering signal, which is an intrinsic optical characteristic of the material. In addition, the PD-L1 / PD-1 binding blocking effect of the TMD nanosheet antibody mimetic, according to the present invention, can be identified at the cell level and the cancer cell transplantation animal model level, and thus the TMD nanosheet antibody mimetic can also function as an immunotherapeutic agent.

A pheromonicin against SARS-COV-2. Antibody mimetics, i.e., two 28-residues are designed for the first time by selecting the E protein and M protein of SARS-COV-2, which are relatively conserved and have low probability of mutation, as targets. Pharmacodynamic experiments performed using three SARS-COV-2 strains (the epidemic strain GD108, the South Africa strain SA and the India strain IND) respectively prove that fusion proteins obtained by linking the 28-residues to colicin can provide effective protective efficacy against pulmonary lesions induced by SARS-COV-2, and can be used as drugs for treating and preventing SARS-COV-2.

The present invention relates to the field of biomedicine, and more specifically, to a polypeptide with binding affinity for Epstein-Barr virus nuclear antigen 1 (EBNA1) and its use. The present invention provides a polypeptide with binding affinity for EBNA1, using EBNA1 as the target antigen. The inventors used the Z domain of Staphylococcus protein A as a scaffold, randomly mutated its surface amino acid residues to mimic antibody binding sites, constructed a mutant library using phage display technology, and subjected this library to affinity screening using EBNA1 as the target antigen. After extensive screening, a polypeptide with high affinity for EBNA1 was ultimately obtained. After in-depth research, the present invention discloses a polypeptide with binding affinity for EBNA1. Furthermore, the present invention provides the use of this polypeptide as a drug or molecular targeting agent for diagnosis or treatment.

To provide: a genetically modified cell in which a nucleic acid encoding a TNFR2 binding agent (e.g., a Stefin A protein variant that specifically binds to TNFR2) or a fusion protein including the same is introduced into a host cell; a conditioned cell culture medium thereof; pharmaceutical preparations of the genetically modified cell; and uses of the genetically modified cell for treatment of immune diseases, including inflammatory diseases, autoimmune diseases and cancers.SOLUTION: The invention provides population of genetically modified mesenchymal stem cells (MSCs), where the mesenchymal stem cells comprise an exogenous nucleic acid comprising a sequence that encodes a TNFR2 binding agent, where the TNFR2 binding agent comprises one or more binding domains from an antibody or antibody mimetic.SELECTED DRAWING: Figure 11

The present invention relates to bispecific antibodies that can bind to coagulation factor IX (FIX) and / or its activated form factor IXa (FIXa) and factor X (FX) and / or its activated form factor Xa (FXa) and promote the activation of FX by FIXa, as well as methods and compositions for treating subjects suffering from coagulopathy such as hemophilia A with or without inhibitors.

The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dosage regimens and compositions for use in such methods.

The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dosage regimens and compositions for use in such methods.

The present disclosure relates to a genetically modified stem cells (e.g., mesenchymal stromal cells (MSCs) or pluripotent stem cells (PSCs)) and populations thereof, that comprise an exogenous nucleic acid that encodes a binding protein that binds to a target. Targets include, for example, proteins expressed on activated immune cells. Binding proteins expressed by genetically modified stem cells as described herein can include one or more binding domains from an antibody or antibody mimetic. Also provided are methods of making genetically modified stem cells, pharmaceutical preparations including genetically modified stem cells, and methods of using the same, for example, in the treatment of immune diseases, including inflammatory, autoimmunity and cancer.

Provided herein is a conjugate comprising an at least trivalent branching group, an antibody or antibody mimetic that specifically binds to a tumor antigen expressed on a tumor cell, an effect moiety, and an potency enhancing group.

Described herein is a method for detecting the presence of circulating extracellular vesicles in a subject. The method comprises contacting a biological sample from the subject with an antibody mimetic that specifically binds to a cell surface marker on the vesicles, wherein the antibody mimetic is coupled to a detectable label; and detecting presence of extracellular vesicles in the sample by detecting the presence of the detectable label coupled to the antibody mimetic bound to the vesicles.

The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.

The present invention generally relates to the use of bispecific FVIII mimic antibodies in the treatment of hemophilia, such as hemophilia A with or without inhibitors, and particularly to methods of treating the disease, such as dosage regimens and compositions used in such methods.

The invention belongs to the technical field of medicines and skin care products, and particularly relates to application of a proprotein convertase subtilisin / kexin9 type (PCSK9) inhibitor in anti-aging and tissue repair products. The PCSK9 gene is characterized in that the PCSK9 belongs to a proprotein converting enzyme family. The PCSK9 inhibitor is a PCSK9 small molecule compound inhibitor, a PCSK9 monoclonal antibody, a PCSK9 small interfering RNA (Ribonucleic Acid), a PCSK9 mimic peptide inhibitor, a PCSK9 mimic antibody protein, a PCSK9 antisense oligonucleotide or a PCSK9 vaccine, and is applied to preparation of anti-aging and tissue repair products. A systematic or external PCSK9 inhibitor product can be further developed and is used for resisting aging and repairing tissues.

The invention belongs to the technical field of medicines, and particularly relates to an effect of ACC in hair growth and application of an ACC inhibitor in preparation of hair growth products. The method is characterized in that ACC is acetyl coenzyme A carboxylase and is a key enzyme in a liver tissue fatty acid synthesis process. The ACC inhibitor comprises but not limited to an ACC small molecule compound inhibitor, an ACC monoclonal antibody, ACC small interfering RNA, an ACC mimic peptide inhibitor, ACC mimic antibody protein, ACC antisense oligonucleotide or an ACC vaccine, and is applied to preparation of hair growth products. A systematic or external ACC inhibitor product can be further developed and is used for promoting hair growth and treating alopecia diseases.

The present invention relates generally to the use of bispecific FVIII mimetic antibodies in the treatment of hemophilia, such as hemophilia A with or without an inhibitor, in particular to methods of treating such diseases, such as a dosage regimen and composition once per two months for use in such methods.

To provide antibodies that mimic desirable characteristics of small molecule prodrugs in the field of antibody-based therapeutics.SOLUTION: Antibodies, activatable antibodies (AA), bispecific antibodies, and bispecific activatable antibodies (BAA) are provided. Methods for making and using these antibodies, AAs, bispecific antibodies, and BAAs are also provided. In one aspect, an activatable antibody (AA) is provided, comprising: a) an antibody or antigen-binding fragment (AB) thereof that specifically binds to the epsilon chain of CD3 (CD3ε); b) a masking moiety (MM) coupled to the AB, the MM reducing or inhibiting binding of the AB to the CD3ε when the AA is in an uncleaved state, and the MM comprising a specific amino acid sequence; and c) a cleavable moiety (CM) coupled to the AB, the CM being a polypeptide that functions as a substrate for a protease.SELECTED DRAWING: Figure 17